The market for Lipid-Lowering Agents in BRICS countries is constantly evolving and adapting to new customer preferences and local special circumstances.
Customer preferences: Patients in BRICS countries are becoming more health-conscious and are increasingly seeking preventative treatments for chronic conditions such as high cholesterol. This has led to a growing demand for Lipid-Lowering Agents, which are medications that help lower cholesterol levels in the blood.
Trends in the market: In Brazil, the Lipid-Lowering Agents market is expected to grow due to the increasing prevalence of cardiovascular diseases. The market in Russia is being driven by the government's efforts to improve the country's healthcare system, which has led to an increase in the availability of these medications. In India, the market is being driven by the increasing adoption of western lifestyles, which has led to an increase in the prevalence of high cholesterol. The market in China is being driven by the government's efforts to reduce the burden of cardiovascular diseases, which has led to an increase in the availability of these medications.
Local special circumstances: In Brazil, the government's universal healthcare system has led to a high demand for affordable Lipid-Lowering Agents. In Russia, the market is dominated by local manufacturers, which has led to a focus on the development of generic medications. In India, the market is highly fragmented with a large number of local manufacturers, which has led to intense competition and price sensitivity. In China, the market is dominated by multinational pharmaceutical companies, which has led to a focus on the development of innovative medications.
Underlying macroeconomic factors: The Lipid-Lowering Agents market in BRICS countries is being driven by a number of macroeconomic factors. These include the increasing prevalence of chronic diseases, rising healthcare expenditure, growing disposable incomes, and increasing government initiatives to improve healthcare systems. However, the market is also facing challenges such as regulatory hurdles, pricing pressures, and the increasing availability of alternative therapies. Overall, the Lipid-Lowering Agents market in BRICS countries is expected to continue to grow in the coming years, driven by increasing demand from health-conscious consumers and the growing need for preventative treatments for chronic conditions.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
